Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.33 |
| ▸ | GABRD | O14764 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.33 |
| ▸ | GABRE | P78334 | 2/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.33 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.33 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.33 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16159981 | 0.81 | — | — | |
| SCHEMBL8206258 | 0.81 | — | — | |
| SCHEMBL7105300 | 0.79 | CHRM1 (0.31) | — | |
| Trimethylammonium SCHEMBL27741450 | 0.77 | GABRP (0.33) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10208136 | 0.77 | — | — | |
| SCHEMBL747179 | 0.77 | — | — | |
| SCHEMBL4356171 | 0.73 | — | — | |
| SCHEMBL1345206 | 0.73 | — | — | |
| SCHEMBL127941 | 0.73 | — | — | |
| SCHEMBL4347745 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10899863-B2 | Oil soluble rheology modifying star macromolecules | PILOT POLYMER TECHNOLOGIES, INC. (US) | 2021-01-26 | — | — | US | claimed |
| US-20250127806-A1 | INJECTABLE LIQUID PHARMACEUTICAL COMPOSITION CONTAINING GEMCITABINE AND A CYTIDINE DEAMINASE INHIBITOR | ST JOHNS UNIV (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2023076332-A1 | INJECTABLE LIQUID PHARMACEUTICAL COMPOSTION CONTAINING GEMCITABINE AND A CYTIDINE DEAMINASE INHIBITOR | ST. JOHN'S UNIVERSITY (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20220288538-A1 | POROUS MEMBRANE, PRODUCTION METHOD THEREFOR, SEPARATION MEMBRANE, LAYERED MODULE, AND GAS PERMEATION MODULE | UNIV KYUSHU NAT UNIV CORP (JP) | 2022-09-15 | — | — | US | disclosed |
| EP-4026609-A1 | POROUS MEMBRANE, PRODUCTION METHOD THEREFOR, SEPARATION MEMBRANE, LAYERED MODULE, AND GAS PERMEATION MODULE | Kyushu University, National University Corporation (JP) | 2022-07-13 | — | — | EP | disclosed |
| EP-2624875-A1 | TIME-SELECTIVE BIORESORBABLE OR COLLAPSIBLE DRUG DELIVERY SYSTEMS AND METHODS | Taris Biomedical, Inc. (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20120089122-A1 | TIME-SELECTIVE BIORESORBABLE OR COLLAPSIBLE DRUG DELIVERY SYSTEMS AND METHODS | TARIS BIOMEDICAL, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2012048114-A1 | TIME-SELECTIVE BIORESORBABLE OR COLLAPSIBLE DRUG DELIVERY SYSTEMS AND METHODS | TARIS BIOMEDICAL, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| US-7829741-B2 | Process for producing α, α-difluoroamine | NATIONAL UNIVERSITY CORPORATION (JP) | 2010-11-09 | — | — | US | disclosed |
| EP-1433826-B1 | Ink set for ink-jet recording, ink-jet recording method, recording unit, ink-jet recording apparatus and bleeding reducing method | CANON KK (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-20090177012-A1 | PROCESS FOR PRODUCING ALPHA, ALPHA-DIFLUOROAMINE | NATIONAL UNIVERSITY CORPORATION, HOKKAIDO UNIVERSITY (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1813596-A1 | PROCESS FOR PRODUCING ALPHA, ALPHA- DIFLUOROAMINE | National University Corporation Hokkaido University (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-1090966-B1 | Ink set for ink-jet recording, ink-jet recording method, recording unit, ink-jet recording apparatus and bleeding reducing method | CANON KK (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-20040209016-A1 | Recording medium excellent in light-resistance and method for production thereof | MITSUI CHEMICALS, INC. (JP) | 2004-10-21 | — | — | US | disclosed |
| EP-1433826-A2 | Ink set for ink-jet recording, ink-jet recording method, recording unit, ink-jet recording apparatus and bleeding reducing method | CANON KABUSHIKI KAISHA (JP) | 2004-06-30 | — | — | EP | disclosed |
| EP-1418056-A1 | RECORDING MEDIUM EXCELLENT IN LIGHT−RESISTANCE AND METHOD FOR PRODUCTION THEREOF | Mitsui Chemicals, Inc. (JP) | 2004-05-12 | — | — | EP | disclosed |
| US-6460987-B1 | Ink set for ink-jet recording, ink-jet recording method, recording unit, ink-jet recording apparatus and bleeding reducing method | CANON KABUSHIKI KAISHA (JP) | 2002-10-08 | — | — | US | disclosed |
| EP-1090966-A1 | Ink set for ink-jet recording, ink-jet recording method, recording unit, ink-jet recording apparatus and bleeding reducing method | CANON KABUSHIKI KAISHA (JP) | 2001-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899863-B2 | Oil soluble rheology modifying star macromolecules | STARD3, STARD7, CETP | GABRP 2379/4885GABRD 3944/4885GABRA1 3009/4885 |
| US-20090177012-A1 | PROCESS FOR PRODUCING ALPHA, ALPHA-DIFLUOROAMINE | FUCA1, FUCA2, DBH | GABRP 1608/4885GABRD 668/4885GABRA1 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.